This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rimsky, L. T.
Right arrow Articles by Matthews, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rimsky, L. T.
Right arrow Articles by Matthews, T. J.

 Previous Article  |  Next Article 

J Virol, February 1998, p. 986-993, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

Laurence T. Rimsky, Diane C. Shugars,dagger and Thomas J. Matthews*

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710

Received 3 July 1997/Accepted 22 October 1997

A synthetic peptide, DP178, containing amino acids 127 to 162 of the human immunodeficiency virus type 1 (HIV-1) gp41 Env glycoprotein, is a potent inhibitor of virus infection and virus mediated cell-to-cell fusion (C. Wild, T. Greenwell, and T. Matthews, AIDS Res. Hum. Retroviruses 9:1051-1053, 1993). In an effort to understand the mechanism of action of this peptide, we derived resistant variants of HIV-1IIIB and NL4-3 by serial virus passage in the presence of increasing doses of the peptide. Sequence analysis of the resistant isolates suggested that a contiguous 3-amino-acid sequence within the amino-terminal heptad repeat motif of gp41 was associated with resistance. Site-directed mutagenesis studies confirmed this observation and indicated that changes in two of these three residues were necessary for development of the resistant phenotype. Direct binding of DP178 to recombinant protein and synthetic peptide analogs containing the wild-type and mutant heptad repeat sequences revealed a strong correlation between DP178 binding and the biological sensitivity of the corresponding virus isolates to DP178. The results are discussed from the standpoints of the mechanism of action of DP178 and recent crystallographic information for a core structure of the gp41 ectodomain.

* Corresponding author. Mailing address: Center for AIDS Research, P.O. Box 2926, Department of Surgery, Duke University Medical Center, Durham, NC 27710. Phone: (919) 684-4215. Fax: (919) 684-4288. E-mail: matth006{at}mc.duke.edu.

dagger Present address: Department of Dental Ecology and Microbiology/Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7456.




This article has been cited by other articles:

  • Eggink, D., Langedijk, J. P. M., Bonvin, A. M. J. J., Deng, Y., Lu, M., Berkhout, B., Sanders, R. W. (2009). Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors. J. Biol. Chem. 284: 26941-26950 [Abstract] [Full Text]  
  • Pan, C., Cai, L., Lu, H., Qi, Z., Jiang, S. (2009). Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains. J. Virol. 83: 7862-7872 [Abstract] [Full Text]  
  • Hermann, F. G., Egerer, L., Brauer, F., Gerum, C., Schwalbe, H., Dietrich, U., von Laer, D. (2009). Mutations in gp120 Contribute to the Resistance of Human Immunodeficiency Virus Type 1 to Membrane-Anchored C-Peptide maC46. J. Virol. 83: 4844-4853 [Abstract] [Full Text]  
  • Ray, N., Blackburn, L. A., Doms, R. W. (2009). HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide. J. Virol. 83: 2989-2995 [Abstract] [Full Text]  
  • Naito, T., Izumi, K., Kodama, E., Sakagami, Y., Kajiwara, K., Nishikawa, H., Watanabe, K., Sarafianos, S. G., Oishi, S., Fujii, N., Matsuoka, M. (2009). SC29EK, a Peptide Fusion Inhibitor with Enhanced {alpha}-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide. Antimicrob. Agents Chemother. 53: 1013-1018 [Abstract] [Full Text]  
  • Champagne, K., Shishido, A., Root, M. J. (2009). Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled Coil. J. Biol. Chem. 284: 3619-3627 [Abstract] [Full Text]  
  • He, Y., Liu, S., Li, J., Lu, H., Qi, Z., Liu, Z., Debnath, A. K., Jiang, S. (2008). Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition. J. Virol. 82: 11129-11139 [Abstract] [Full Text]  
  • He, Y., Cheng, J., Lu, H., Li, J., Hu, J., Qi, Z., Liu, Z., Jiang, S., Dai, Q. (2008). Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. USA 105: 16332-16337 [Abstract] [Full Text]  
  • Floyd, D. L., Ragains, J. R., Skehel, J. J., Harrison, S. C., van Oijen, A. M. (2008). Single-particle kinetics of influenza virus membrane fusion. Proc. Natl. Acad. Sci. USA 105: 15382-15387 [Abstract] [Full Text]  
  • Baldwin, C., Berkhout, B. (2008). Mechanistic Studies of a T20-Dependent Human Immunodeficiency Virus Type 1 Variant. J. Virol. 82: 7735-7740 [Abstract] [Full Text]  
  • He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., Dai, Q. (2008). Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors. J. Virol. 82: 6349-6358 [Abstract] [Full Text]  
  • Eggink, D., Baldwin, C. E., Deng, Y., Langedijk, J. P. M., Lu, M., Sanders, R. W., Berkhout, B. (2008). Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants. J. Virol. 82: 6678-6688 [Abstract] [Full Text]  
  • Huang, W., Toma, J., Fransen, S., Stawiski, E., Reeves, J. D., Whitcomb, J. M., Parkin, N., Petropoulos, C. J. (2008). Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein. J. Virol. 82: 5584-5593 [Abstract] [Full Text]  
  • He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S., Zhang, L. (2008). Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. J. Biol. Chem. 283: 11126-11134 [Abstract] [Full Text]  
  • Gray, E. S., Moore, P. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Meyers, T., Shaw, G. M., Morris, L. (2008). 4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response. J. Virol. 82: 2367-2375 [Abstract] [Full Text]  
  • Lai, W., Huang, L., Ho, P., Li, Z., Montefiori, D., Chen, C.-H. (2008). Betulinic Acid Derivatives That Target gp120 and Inhibit Multiple Genetic Subtypes of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 52: 128-136 [Abstract] [Full Text]  
  • Wexler-Cohen, Y., Shai, Y. (2007). Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J. 21: 3677-3684 [Abstract] [Full Text]  
  • Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., Kay, M. S. (2007). Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA 104: 16828-16833 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Chinnadurai, R., Rajan, D., Munch, J., Kirchhoff, F. (2007). Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue. J. Virol. 81: 6563-6572 [Abstract] [Full Text]  
  • Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., Doms, R. W. (2007). Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. J. Virol. 81: 3240-3250 [Abstract] [Full Text]  
  • Liu, S., Jing, W., Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., Jiang, S. (2007). HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES. J. Biol. Chem. 282: 9612-9620 [Abstract] [Full Text]  
  • Marcial, M., Lu, J., Deeks, S. G., Ziermann, R., Kuritzkes, D. R. (2006). Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations.. J. Clin. Microbiol. 44: 3384-3387 [Abstract] [Full Text]  
  • Labrosse, B., Morand-Joubert, L., Goubard, A., Rochas, S., Labernardiere, J.-L., Pacanowski, J., Meynard, J.-L., Hance, A. J., Clavel, F., Mammano, F. (2006). Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.. J. Virol. 80: 8807-8819 [Abstract] [Full Text]  
  • Steger, H. K., Root, M. J. (2006). Kinetic Dependence to HIV-1 Entry Inhibition. J. Biol. Chem. 281: 25813-25821 [Abstract] [Full Text]  
  • Cole, A. L., Yang, O. O., Warren, A. D., Waring, A. J., Lehrer, R. I., Cole, A. M. (2006). HIV-1 Adapts to a Retrocyclin with Cationic Amino Acid Substitutions That Reduce Fusion Efficiency of gp41.. J. Immunol. 176: 6900-6905 [Abstract] [Full Text]  
  • Doyle, J., Prussia, A., White, L. K., Sun, A., Liotta, D. C., Snyder, J. P., Compans, R. W., Plemper, R. K. (2006). Two Domains That Control Prefusion Stability and Transport Competence of the Measles Virus Fusion Protein. J. Virol. 80: 1524-1536 [Abstract] [Full Text]  
  • Amberg, S. M., Netter, R. C., Simmons, G., Bates, P. (2006). Expanded Tropism and Altered Activation of a Retroviral Glycoprotein Resistant to an Entry Inhibitor Peptide. J. Virol. 80: 353-359 [Abstract] [Full Text]  
  • Repits, J., Oberg, M., Esbjornsson, J., Medstrand, P., Karlsson, A., Albert, J., Fenyo, E. M., Jansson, M. (2005). Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 86: 2859-2869 [Abstract] [Full Text]  
  • Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., Greenberg, M. L. (2005). Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro. J. Virol. 79: 12447-12454 [Abstract] [Full Text]  
  • Lemey, P., Derdelinckx, I., Rambaut, A., Van Laethem, K., Dumont, S., Vermeulen, S., Van Wijngaerden, E., Vandamme, A.-M. (2005). Molecular Footprint of Drug-Selective Pressure in a Human Immunodeficiency Virus Transmission Chain. J. Virol. 79: 11981-11989 [Abstract] [Full Text]  
  • Lohrengel, S., Hermann, F., Hagmann, I., Oberwinkler, H., Scrivano, L., Hoffmann, C., von Laer, D., Dittmar, M. T. (2005). Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides. J. Virol. 79: 10237-10246 [Abstract] [Full Text]  
  • Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., Fischer, M., Stiegler, G., Katinger, H., Olson, W. C., Weber, R., Aceto, L., Gunthard, H. F., Trkola, A. (2005). Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. J. Virol. 79: 8454-8469 [Abstract] [Full Text]  
  • Perez-Romero, P., Fuller, A. O. (2005). The C Terminus of the B5 Receptor for Herpes Simplex Virus Contains a Functional Region Important for Infection. J. Virol. 79: 7431-7437 [Abstract] [Full Text]  
  • Kinomoto, M., Yokoyama, M., Sato, H., Kojima, A., Kurata, T., Ikuta, K., Sata, T., Tokunaga, K. (2005). Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor. J. Virol. 79: 5996-6004 [Abstract] [Full Text]  
  • Desmezieres, E., Gupta, N., Vassell, R., He, Y., Peden, K., Sirota, L., Yang, Z., Wingfield, P., Weiss, C. D. (2005). Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120. J. Virol. 79: 4774-4781 [Abstract] [Full Text]  
  • Reeves, J. D., Lee, F.-H., Miamidian, J. L., Jabara, C. B., Juntilla, M. M., Doms, R. W. (2005). Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization. J. Virol. 79: 4991-4999 [Abstract] [Full Text]  
  • Hamburger, A. E., Kim, S., Welch, B. D., Kay, M. S. (2005). Steric Accessibility of the HIV-1 gp41 N-trimer Region. J. Biol. Chem. 280: 12567-12572 [Abstract] [Full Text]  
  • Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S., Jiang, S. (2005). Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120. J. Biol. Chem. 280: 11259-11273 [Abstract] [Full Text]  
  • Xu, L., Pozniak, A., Wildfire, A., Stanfield-Oakley, S. A., Mosier, S. M., Ratcliffe, D., Workman, J., Joall, A., Myers, R., Smit, E., Cane, P. A., Greenberg, M. L., Pillay, D. (2005). Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41. Antimicrob. Agents Chemother. 49: 1113-1119 [Abstract] [Full Text]  
  • Lenz, O., Dittmar, M. T., Wagner, A., Ferko, B., Vorauer-Uhl, K., Stiegler, G., Weissenhorn, W. (2005). Trimeric Membrane-anchored gp41 Inhibits HIV Membrane Fusion. J. Biol. Chem. 280: 4095-4101 [Abstract] [Full Text]  
  • Nameki, D., Kodama, E., Ikeuchi, M., Mabuchi, N., Otaka, A., Tamamura, H., Ohno, M., Fujii, N., Matsuoka, M. (2005). Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. J. Virol. 79: 764-770 [Abstract] [Full Text]  
  • Andersson, E., Horal, P., Jejcic, A., Hoglund, S., Balzarini, J., Vahlne, A., Svennerholm, B. (2005). Glycine-Amide Is an Active Metabolite of the Antiretroviral Tripeptide Glycyl-Prolyl-Glycine-Amide. Antimicrob. Agents Chemother. 49: 40-44 [Abstract] [Full Text]  
  • Netter, R. C., Amberg, S. M., Balliet, J. W., Biscone, M. J., Vermeulen, A., Earp, L. J., White, J. M., Bates, P. (2004). Heptad Repeat 2-Based Peptides Inhibit Avian Sarcoma and Leukosis Virus Subgroup A Infection and Identify a Fusion Intermediate. J. Virol. 78: 13430-13439 [Abstract] [Full Text]  
  • Baldwin, C. E., Sanders, R. W., Deng, Y., Jurriaans, S., Lange, J. M., Lu, M., Berkhout, B. (2004). Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor. J. Virol. 78: 12428-12437 [Abstract] [Full Text]  
  • Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., Clementi, M. (2004). Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. Antimicrob. Agents Chemother. 48: 3253-3259 [Abstract] [Full Text]  
  • Okazaki, K., Kida, H. (2004). A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication. J. Gen. Virol. 85: 2131-2137 [Abstract] [Full Text]  
  • Greenberg, M. L., Cammack, N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54: 333-340 [Abstract] [Full Text]  
  • Heil, M. L., Decker, J. M., Sfakianos, J. N., Shaw, G. M., Hunter, E., Derdeyn, C. A. (2004). Determinants of Human Immunodeficiency Virus Type 1 Baseline Susceptibility to the Fusion Inhibitors Enfuvirtide and T-649 Reside outside the Peptide Interaction Site. J. Virol. 78: 7582-7589 [Abstract] [Full Text]  
  • Yuan, W., Craig, S., Si, Z., Farzan, M., Sodroski, J. (2004). CD4-Induced T-20 Binding to Human Immunodeficiency Virus Type 1 gp120 Blocks Interaction with the CXCR4 Coreceptor. J. Virol. 78: 5448-5457 [Abstract] [Full Text]  
  • Reeves, J. D., Miamidian, J. L., Biscone, M. J., Lee, F.-H., Ahmad, N., Pierson, T. C., Doms, R. W. (2004). Impact of Mutations in the Coreceptor Binding Site on Human Immunodeficiency Virus Type 1 Fusion, Infection, and Entry Inhibitor Sensitivity. J. Virol. 78: 5476-5485 [Abstract] [Full Text]  
  • Lu, J., Sista, P., Giguel, F., Greenberg, M., Kuritzkes, D. R. (2004). Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20). J. Virol. 78: 4628-4637 [Abstract] [Full Text]  
  • Clavel, F., Hance, A. J. (2004). HIV Drug Resistance. NEJM 350: 1023-1035 [Full Text]  
  • de Rosny, E., Vassell, R., Jiang, S., Kunert, R., Weiss, C. D. (2004). Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes. J. Virol. 78: 2627-2631 [Abstract] [Full Text]  
  • Egelhofer, M., Brandenburg, G., Martinius, H., Schult-Dietrich, P., Melikyan, G., Kunert, R., Baum, C., Choi, I., Alexandrov, A., von Laer, D. (2004). Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides. J. Virol. 78: 568-575 [Abstract] [Full Text]  
  • Bar, S., Alizon, M. (2004). Role of the Ectodomain of the gp41 Transmembrane Envelope Protein of Human Immunodeficiency Virus Type 1 in Late Steps of the Membrane Fusion Process. J. Virol. 78: 811-820 [Abstract] [Full Text]  
  • Duffalo, M. L, James, C. W (2003). Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection. The Annals of Pharmacotherapy 37: 1448-1456 [Abstract] [Full Text]  
  • Moore, J. P., Doms, R. W. (2003). The entry of entry inhibitors: A fusion of science and medicine. Proc. Natl. Acad. Sci. USA 100: 10598-10602 [Abstract] [Full Text]  
  • Bosch, B. J., van der Zee, R., de Haan, C. A. M., Rottier, P. J. M. (2003). The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. J. Virol. 77: 8801-8811 [Abstract] [Full Text]  
  • Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arasteh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., Huson, L., DeMasi, R., Wat, C., Delehanty, J., Drobnes, C., Salgo, M., the TORO 2 Study Group, (2003). Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia. NEJM 348: 2186-2195 [Abstract] [Full Text]  
  • Kilby, J. M., Eron, J. J. (2003). Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. NEJM 348: 2228-2238 [Full Text]  
  • Douglas, J. L., Panis, M. L., Ho, E., Lin, K.-Y., Krawczyk, S. H., Grant, D. M., Cai, R., Swaminathan, S., Cihlar, T. (2003). Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein. J. Virol. 77: 5054-5064 [Abstract] [Full Text]  
  • Trivedi, V. D., Cheng, S.-F., Wu, C.-W., Karthikeyan, R., Chen, C.-J., Chang, D.-K. (2003). The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng Des Sel 16: 311-317 [Abstract] [Full Text]  
  • Giannecchini, S., Di Fenza, A., D'Ursi, A. M., Matteucci, D., Rovero, P., Bendinelli, M. (2003). Antiviral Activity and Conformational Features of an Octapeptide Derived from the Membrane-Proximal Ectodomain of the Feline Immunodeficiency Virus Transmembrane Glycoprotein. J. Virol. 77: 3724-3733 [Abstract] [Full Text]  
  • He, Y., Vassell, R., Zaitseva, M., Nguyen, N., Yang, Z., Weng, Y., Weiss, C. D. (2003). Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites. J. Virol. 77: 1666-1671 [Abstract] [Full Text]  
  • Labrosse, B., Labernardiere, J.-L., Dam, E., Trouplin, V., Skrabal, K., Clavel, F., Mammano, F. (2002). Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors. J. Virol. 77: 1610-1613 [Abstract] [Full Text]  
  • Reeves, J. D., Gallo, S. A., Ahmad, N., Miamidian, J. L., Harvey, P. E., Sharron, M., Pohlmann, S., Sfakianos, J. N., Derdeyn, C. A., Blumenthal, R., Hunter, E., Doms, R. W. (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99: 16249-16254 [Abstract] [Full Text]  
  • Fikkert, V., Cherepanov, P., Van Laethem, K., Hantson, A., Van Remoortel, B., Pannecouque, C., De Clercq, E., Debyser, Z., Vandamme, A.-M., Witvrouw, M. (2002). env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors. Antimicrob. Agents Chemother. 46: 3954-3962 [Abstract] [Full Text]  
  • Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., Kappes, J. C. (2002). Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. Antimicrob. Agents Chemother. 46: 1896-1905 [Abstract] [Full Text]  
  • Liu, J., Wang, S., Hoxie, J. A., LaBranche, C. C., Lu, M. (2002). Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex. J. Biol. Chem. 277: 12891-12900 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Lu, M., Stoller, M. O., Wang, S., Liu, J., Fagan, M. B., Nunberg, J. H. (2001). Structural and Functional Analysis of Interhelical Interactions in the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein by Alanine-Scanning Mutagenesis. J. Virol. 75: 11146-11156 [Abstract] [Full Text]  
  • Eckert, D. M., Kim, P. S. (2001). Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. USA 98: 11187-11192 [Abstract] [Full Text]  
  • Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., Hunter, E. (2001). Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the Coreceptor. J. Virol. 75: 8605-8614 [Abstract] [Full Text]  
  • Maerz, A. L., Drummer, H. E., Wilson, K. A., Poumbourios, P. (2001). Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 Reveals a Critical Role in gp120-gp41 Association. J. Virol. 75: 6635-6644 [Abstract] [Full Text]  
  • Bultmann, H., Busse, J. S., Brandt, C. R. (2001). Modified FGF4 Signal Peptide Inhibits Entry of Herpes Simplex Virus Type 1. J. Virol. 75: 2634-2645 [Abstract] [Full Text]  
  • Hildinger, M., Dittmar, M. T., Schult-Dietrich, P., Fehse, B., Schnierle, B. S., Thaler, S., Stiegler, G., Welker, R., von Laer, D. (2001). Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry. J. Virol. 75: 3038-3042 [Abstract] [Full Text]  
  • Root, M. J., Kay, M. S., Kim, P. S. (2001). Protein Design of an HIV-1 Entry Inhibitor. Science 291: 884-888 [Abstract] [Full Text]  
  • Holz-Smith, S. L., Sun, I-C., Jin, L., Matthews, T. J., Lee, K.-H., Chen, C. H. (2001). Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564. Antimicrob. Agents Chemother. 45: 60-66 [Abstract] [Full Text]  
  • Melikyan, G. B., Markosyan, R. M., Hemmati, H., Delmedico, M. K., Lambert, D. M., Cohen, F. S. (2000). Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion. JCB 151: 413-424 [Abstract] [Full Text]  
  • Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Wu, X., O'Brien, W. A., Ratner, L., Kappes, J. C., Shaw, G. M., Hunter, E. (2000). Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120. J. Virol. 74: 8358-8367 [Abstract] [Full Text]  
  • D'Souza, M. P., Cairns, J. S., Plaeger, S. F. (2000). Current Evidence and Future Directions for Targeting HIV Entry: Therapeutic and Prophylactic Strategies. JAMA 284: 215-222 [Abstract] [Full Text]  
  • Matthews, J. M., Young, T. F., Tucker, S. P., Mackay, J. P. (2000). The Core of the Respiratory Syncytial Virus Fusion Protein Is a Trimeric Coiled Coil. J. Virol. 74: 5911-5920 [Abstract] [Full Text]  
  • Weng, Y., Yang, Z., Weiss, C. D. (2000). Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41. J. Virol. 74: 5368-5372 [Abstract] [Full Text]  
  • Kingsley, D. H., Behbahani, A., Rashtian, A., Blissard, G. W., Zimmerberg, J. (1999). A Discrete Stage of Baculovirus GP64-mediated Membrane Fusion. Mol. Biol. Cell 10: 4191-4200 [Abstract] [Full Text]  
  • Jinno, A., Haraguchi, Y., Shiraki, H., Hoshino, H. (1999). Inhibition of Cell-Free Human T-Cell Leukemia Virus Type 1 Infection at a Postbinding Step by the Synthetic Peptide Derived from an Ectodomain of the gp21 Transmembrane Glycoprotein. J. Virol. 73: 9683-9689 [Abstract] [Full Text]  
  • Ji, H., Shu, W., Burling, F. T., Jiang, S., Lu, M. (1999). Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion. J. Virol. 73: 8578-8586 [Abstract] [Full Text]  
  • Muñoz-Barroso, I., Salzwedel, K., Hunter, E., Blumenthal, R. (1999). Role of the Membrane-Proximal Domain in the Initial Stages of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Membrane Fusion. J. Virol. 73: 6089-6092 [Abstract] [Full Text]  
  • Lu, M., Ji, H., Shen, S. (1999). Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus Type 1 gp41: Implications for Viral Membrane Fusion. J. Virol. 73: 4433-4438 [Abstract] [Full Text]  
  • Kobe, B., Center, R. J., Kemp, B. E., Poumbourios, P. (1999). Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc. Natl. Acad. Sci. USA 96: 4319-4324 [Abstract] [Full Text]  
  • Chan, D. C., Chutkowski, C. T., Kim, P. S. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 95: 15613-15617 [Abstract] [Full Text]  
  • Weng, Y., Weiss, C. D. (1998). Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41. J. Virol. 72: 9676-9682 [Abstract] [Full Text]  
  • Ghosh, J. K., Peisajovich, S. G., Ovadia, M., Shai, Y. (1998). Structure-Function Study of a Heptad Repeat Positioned Near the Transmembrane Domain of Sendai Virus Fusion Protein Which Blocks Virus-Cell Fusion. J. Biol. Chem. 273: 27182-27190 [Abstract] [Full Text]  
  • Kliger, Y., Gallo, S. A., Peisajovich, S. G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., Shai, Y. (2001). Mode of Action of an Antiviral Peptide from HIV-1. INHIBITION AT A POST-LIPID MIXING STAGE. J. Biol. Chem. 276: 1391-1397 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»